AAAAAA
Results:
1-7
|
Results: 7
Authors:
Edgell, ET
Andersen, SW
Johnstone, BM
Dulisse, B
Revicki, D
Breier, A
Citation: Et. Edgell et al., Olanzapine versus risperidone - A prospective comparison of clinical and economic outcomes in schizophrenia, PHARMACOECO, 18(6), 2000, pp. 567-579
Authors:
Edgell, ET
Hylan, TR
Draugalis, JR
Coons, SJ
Citation: Et. Edgell et al., Initial treatment choice in depression - Impact on medical expenditures, PHARMACOECO, 17(4), 2000, pp. 371-382
Authors:
Hamilton, SH
Edgell, ET
Revicki, DA
Breier, A
Citation: Sh. Hamilton et al., Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample, INT CLIN PS, 15(5), 2000, pp. 245-255
Authors:
Hamilton, SH
Revicki, DA
Edgell, ET
Genduso, LA
Genduso, LA
Tollefson, G
Citation: Sh. Hamilton et al., Clinical and economic outcomes of olanzapine compared with haloperidol forschizophrenia - Results from a randomised clinical trial, PHARMACOECO, 15(5), 1999, pp. 469-480
Authors:
Edgell, ET
Johnstone, BH
Citation: Et. Edgell et Bh. Johnstone, Benefits of olanzapine as first-line schizophrenia therapy, AM J HEAL S, 56(15), 1999, pp. 1559-1560
Authors:
Edgell, ET
Gregor, KJ
Cockburn, I
Citation: Et. Edgell et al., Untitled, CLIN THER, 21(5), 1999, pp. 917-924
Authors:
Edgell, ET
Summers, KH
Hylan, TR
Ober, J
Bootman, JL
Citation: Et. Edgell et al., A framework for drug utilization evaluation in depression - Insights from outcomes research, MED CARE, 37(4), 1999, pp. AS67-AS76
Risultati:
1-7
|